{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:08:43Z","timestamp":1791511723689,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinthera.2020.12.023","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T21:37:20Z","timestamp":1612474640000},"page":"613-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A\u2002Multicenter Phase\u2002II\u2002Clinical Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Wen-yan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-qing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-you","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.12.023_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry eye syndrome preferred Practice Pattern\u00ae","volume":"126","author":"Akpek","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2020.12.023_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2015-308237","article-title":"Functional impairment of reading in patients with dry eye","volume":"101","author":"Mathews","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.6.3.24","article-title":"Impact of glaucoma and dry eye on text-based searching","volume":"6","author":"Sun","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease","volume":"110","author":"Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2020.12.023_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","article-title":"Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies","volume":"127","author":"Schaumberg","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib7","first-page":"73","article-title":"Expert consensus on clinical diagnosis and treatment of dry eye (2013)","volume":"49","year":"2013","journal-title":"Chin J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib8","first-page":"380","article-title":"Research progress of xerophthalmia","volume":"27","author":"Hu","year":"2007","journal-title":"New Adv Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II Report executive summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2020.12.023_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","article-title":"Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study","volume":"31","author":"Lemp","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2020.12.023_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00003226-200009000-00009","article-title":"The diagnosis and management of dry eye: a twenty-five-year review","volume":"19","author":"Pflugfelder","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2020.12.023_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","article-title":"Antiinflammatory therapy for dry eye","volume":"137","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib13","series-title":"RestasisTM (Cyclosporine Ophthalmic Emulsion) 0.05% Sterile, Preservative-free","year":"2018"},{"key":"10.1016\/j.clinthera.2020.12.023_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2020.12.023_bib15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"CsA Phase 3 study group, two randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2020.12.023_bib16","first-page":"1","article-title":"Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomized, vehicle controlled phase III clinical studies","author":"Leonardi","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib17","series-title":"Preferred Practice Pattern\u00ae Guidelines. Dry Eye Syndrome","year":"2013"},{"key":"10.1016\/j.clinthera.2020.12.023_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00003226-199901000-00007","article-title":"Corneal scarring in the collaborative longitudinal evaluation of keratoconus study: baseline prevalence and repeatability of detection","volume":"18","author":"Barr","year":"1999","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2020.12.023_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1542-0124(12)70086-1","article-title":"Research in dry eye: report of the research subcommittee of the international dry eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2020.12.023_bib20","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clinthera.2020.12.023_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2125.1996.04231.x","article-title":"Estimating impossible curves using NONMEM","volume":"42","author":"Schoemaker","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/ps020332","article-title":"Nonlinearity detection: advantages of nonlinear mixed-effects modeling","volume":"2","author":"Jonsson","year":"2000","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.clinthera.2020.12.023_bib24","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib25","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1167\/iovs.03-0270","article-title":"The relationship between habitual patient-reported symptoms and clinical signs of among patients with dry eye of varying severity","volume":"44","author":"Begley","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2020.12.023_bib26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2020.12.023_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1542-0124(12)70187-8","article-title":"The association between symptoms of discomfort and signs in dry eye","volume":"7","author":"Johnson","year":"2009","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2020.12.023_bib28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A\u00a0randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2020.12.023_bib30","unstructured":"Highlights of prescribing information: RESTASIS\u00ae 0.05%. Allergan. http:\/\/www.allergan.com. Accessed August 29, 2019. (https:\/\/www.drugfuture.com\/fda-ndc\/label.aspx?ProductNDC=50090-4476)"},{"key":"10.1016\/j.clinthera.2020.12.023_bib31","article-title":"Evaluation of clinical efficacy and safety of a novel cyclosporin a nanoemulsion in the treatment of dry eye syndrome","volume":"33","author":"Kim","year":"2017","journal-title":"JOPT"},{"key":"10.1016\/j.clinthera.2020.12.023_bib32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2147\/OPTH.S101627","article-title":"The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye","volume":"10","author":"Stonecipher","year":"2016","journal-title":"Clin Ophthalmol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:43Z","timestamp":1758963283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0149291821000072"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A\u2002Multicenter Phase\u2002II\u2002Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}